Literature DB >> 25420419

Individualized factor IX dosing in two brothers: application of longitudinal pharmacokinetic modelling to optimize therapeutic benefit.

J T Brown1, B M Wicklund2,3, S M Abdel-Rahman1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25420419      PMCID： PMC5846128          DOI： 10.1111/hae.12593

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.263


× No keyword cloud information.
  8 in total

1.  A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.

Authors:  J Goudemand; J Peynet; H Chambost; C Négrier; M E Briquel; S Claeyssens; A Derlon-Borel; C Guérois; C Caron; J M Scherrmann; M Debray; F Bridey
Journal:  Thromb Haemost       Date:  1998-12       Impact factor: 5.249

Review 2.  Clinical evaluation of recombinant factor IX.

Authors:  G White; A Shapiro; M Ragni; P Garzone; J Goodfellow; K Tubridy; S Courter
Journal:  Semin Hematol       Date:  1998-04       Impact factor: 3.851

3.  Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.

Authors:  S Björkman; A D Shapiro; E Berntorp
Journal:  Haemophilia       Date:  2001-03       Impact factor: 4.287

Review 4.  Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.

Authors:  A D Shapiro; J Korth-Bradley; M-C Poon
Journal:  Haemophilia       Date:  2005-11       Impact factor: 4.287

5.  Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.

Authors:  M Carlsson; S Björkman; E Berntorp
Journal:  Haemophilia       Date:  1998-03       Impact factor: 4.287

Review 6.  Primary prophylaxis in children with haemophilia.

Authors:  Antonio Coppola; Mirko Di Capua; Ciro De Simone
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

7.  Use of pharmacokinetic modelling to individualize FFP dosing in factor V deficiency.

Authors:  V Shakhnovich; J Daniel; B Wicklund; G Kearns; K Neville
Journal:  Haemophilia       Date:  2012-11-23       Impact factor: 4.287

8.  Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation.

Authors:  S Björkman; M Carlsson; E Berntorp
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953
  8 in total
  1 in total

1.  Design and Usability of an Electronic Health Record-Integrated, Point-of-Care, Clinical Decision Support Tool for Modeling and Simulation of Antihemophilic Factors.

Authors:  Susan M Abdel-Rahman; Harpreet Gill; Shannon L Carpenter; Pathe Gueye; Brian Wicklund; Matt Breitkreutz; Arindam Ghosh; Avinash Kollu
Journal:  Appl Clin Inform       Date:  2020-04-08       Impact factor: 2.342
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.